About synlogic inc - SYBX
Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.
SYBX At a Glance
Synlogic, Inc.
301 Binney Street
Cambridge, Massachusetts 02142
| Phone | 1-617-401-9975 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -1,005,000.00 | |
| Sector | Health Technology | Employees | 1 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SYBX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.105 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.249 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
SYBX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,005,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SYBX Liquidity
| Current Ratio | 4.296 |
| Quick Ratio | 4.296 |
| Cash Ratio | 4.093 |
SYBX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -5.698 |
| Return on Equity | -8.166 |
| Return on Total Capital | -8.472 |
| Return on Invested Capital | -8.166 |
SYBX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |